U.S. flag An official website of the United States government
  1. Home
  2. Drugs
  3. Emergency Preparedness | Drugs
  4. Coronavirus (COVID-19) | Drugs
  1. Emergency Preparedness | Drugs

Coronavirus (COVID-19) | Drugs


In response to the novel coronavirus (COVID-19), FDA quickly created, in March 2020, the Coronavirus Treatment Acceleration Program (CTAP), which was designed to help facilitate the development of drugs and biological products (other than vaccines) for COVID-19 therapeutics. The development of COVID-19 therapeutics that are effective against current and future variants remains a critical priority. CTAP is leveraging the agency’s scientific experience and knowledge of COVID-19 to support current and future clinical trials testing new treatments for COVID-19. From these efforts, we continue to gain valuable knowledge about the safety and effectiveness of potential therapies for COVID-19.

COVID-19 Therapeutics

  • Antiviral Drugs
    Antiviral drugs are medicines (pills, liquid, an inhaled powder, or an intravenous solution) that fight against viruses in your body.
  • Immune Modulators
    Immune modulators are medicines that help activate, boost, or suppress the immune function. In the case of COVID-19 infection, the immune system can become hyperactive which may result in worsening of disease. Immune modulators can help suppress this hyperinflammation.
  • Monoclonal Antibodies (mAbs) targeting SARS-COV-2
    SARS-COV-2-targeting mAbs are laboratory-produced antibodies that can help the immune system's attack on SARS-COV-2. These mAbs block entry of SARS-CoV-2 into human cells, thus neutralizing the virus. SARS-CoV-2 can mutate over time, resulting in genetic variation in the population of circulating viral strains. Some variants can cause resistance to one or more of the mAb therapies authorized to treat COVID-19.
  • Renal Replacement Therapy Solutions
    Continuous renal replacement therapy (CRRT) is a type of “dialysis,” which is a machine treatment that filters and purifies the blood when a patient’s kidneys are damaged or are not functioning normally. CRRT is used for patients with kidney injury in acute care settings. SARS-CoV-2 led to an increased population with critical illness and multiple organ failure, including acute kidney injury, increasing the need for CRRT. In addition, there was an insufficient supply of replacement solutions to meet the emergency need to provide CRRT in critically ill patients.

Sub-Topic Paragraphs

Additional Resources

Additional Resources

COVID-19 Treatment Hub

Provides physicians, patients, and caregivers with information about the latest research in the fight against COVID-19

Paragraph Header

Contact Point
Office of Communications
10001 New Hampshire Ave
Hillandale Building, 4th Fl
Silver Spring, MD 20993

Toll Free
(855) 543-3784
(301) 796-3400

Hours Available

CDER Division of Drug Information

For Latest Updates Follow

Contact Point Twitter


Your source for the latest drug information.
Know the moment it happens.

Back to Top